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Objectives:  Bone marrow stromal cells contain “adult stem cells.” We tested the
hypothesis that coronary-infused bone marrow stromal cells may populate the
infarcted heart and undergo milieu-dependent differentiation to regenerate func-
tional tissues with different phenotypic features.
Methods: Isogenic adult rats were used as donors and recipients to simulate autol-
ogous transplantation clinically. Myocardial infarction was created by proximal
occlusion of left coronary artery in 12 recipient rats. Isolated bone marrow stromal
cells were purified, expanded, and retrovirally transduced with LacZ reporter gene
for cell labeling. Stromal cells were then infused into the briefly distally clamped
ascending aorta of recipient rats 2 weeks after left coronary artery ligation. The
hearts were harvested immediately (n = 2) or 4 weeks (n = 10) later to trace the
implanted cells and identify their phenotypes.
Results: Viable cells labeled with LacZ reporter gene were identified in 8 recipient
hearts. Immediately after cell infusion, the labeled cells were trapped within the
coronary capillaries. After 4 weeks, they could be detected individually or in clus-
ters within myocardial scar expressing fibroblastic phenotype or outside the infarc-
tion area with morphologic features of normal cardiomyocytes. Some were incor-
porated into endocardium and capillary endothelium.
Conclusions: Our findings suggest that bone marrow stromal cells can traffic
through the coronary system to the injured heart and form cardiomyocytes or
fibroblasts, depending on the specific microenvironment. Endothelial progenitor
cells in the stromal cell population may be involved in the postinfarction neovascu-
larization process. Whether therapeutic use of bone marrow stromal cells can
improve the myocardial healing and remodeling process after infarction is worthy
of further investigation.
Cellular cardiomyoplasty,1 wherein donor cells are transplanted intothe myocardium, may augment cardiac function in myocardial dis-ease states. Proposals to use certain sources of donor cells for cel-lular cardiomyoplasty, although appearing promising, are not idealfor clinical application, owing primarily to the need for fetal tissueand/or for immunosuppression.2-5 Marrow stromal cells (MSCs)
constitute a separate group of stem cells other than hematopoietic stem cells in the
bone marrow and have been explored as vehicles for both cell and gene therapy in
recent years.6 Under controlled in vitro conditions, MSCs have been reproducibly
guided to differentiate into multiple mesenchymal lineages, including those of
osteocytes, chondrocytes, adipocytes, myocytes, and even cardiomyocytes.7,8
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Recently, we9 demonstrated that the in vivo myocardial
environment can support the growth and induce the car-
diomyogenic differentiation of MSCs. Compared with other
cell sources, MSCs seem to have many advantages for clin-
ical use in cellular cardiomyoplasty.
Grafting of cells into the myocardium requires some
form of delivery system. The choice for the routes of cell
implantation may depend on the pathologic condition of the
heart. Up to now, most of studies in the field of cellular car-
diomyoplasty were performed by direct injection of various
cells into the myocardium.1-5,9 Although implanted cells
may have the ability to migrate along the ventricular surface
of heart,10 this procedure covers only a limited field and
may require multiple injections, either through epicardium
or via the endocardium. Coronary arterial delivery of donor
cells to the myocardium possesses theoretical advantages, at
least for certain types of heart failure. Thus, to optimize the
strategy for cell implantation, in this study we evaluated 
the feasibility of delivering MSCs by selective infusion into
the coronary circulation. We further tested the hypothesis
that MSCs infused into coronary arteries may repopulate the
heart and that signals originating in the cardiac milieu could
modify the developmental program of the infused MSCs.
Toward this goal, we wished to confirm their residence out-
side the capillary bed and to observe the structural interac-
tions between the host myocardial tissues and the implanted
MSCs.
Methods
Animals
Male inbred Lewis rats, 200 to 250 g, were obtained from Charles
River Laboratories (Laprairie Co, Quebec, Canada). These iso-
genic rats were used as donors and recipients to simulate the autol-
ogous infusion of MSCs in future clinical application. All animals
received humane care in compliance with the “Guide for the Care
and Use of Laboratory Animals” prepared by the Institute of
Laboratory Animal Resources, National Research Council, and
published by the National Academy Press, revised 1996, and the
“Guide to the Care and Use of Experimental Animals” of the
Canadian Council on Animal Care.
Myocardial Infarction Model
Twelve recipient rats were anesthetized with isoflurane (MTC
Pharmaceuticals, Cambridge, Ontario, Canada). Rats were intubat-
ed and their lungs were ventilated at 85 breaths/min. The heart was
exposed via a left thoracotomy incision. The left coronary artery
was identified and ligated proximally with a 7-0 polypropylene
suture. Regional myocardial ischemia was confirmed by the rapid
occurrence of akinesia in the area at risk. The wound was then
closed.
Isolation and Culture of MSCs 
Isolation and primary culture of MSCs from the femoral and tibial
bones of donor rats were performed according to Caplan’s
method.11 After an overdose with pentobarbital (100 mg/kg given
intraperitoneally), the femoral and tibial bones were collected.
Both ends of the bones were cut away from the diaphyses. The
bone marrow plugs were hydrostatically expelled from the bones
with complete medium. The marrow plugs were disaggregated and
the dispersed cells were centrifuged and resuspended twice in
complete medium. These cells in 10 mL of complete medium were
then introduced into tissue culture dishes. Medium was complete-
ly replaced every 3 days and the nonadherent cells were discarded.
Each primary culture was replated twice (first and second pas-
sages) to 3 new plates when the cell density within colonies
became 80% to 90% confluent. After the twice-passaged cells
became nearly confluent, they were harvested and used for the
coronary infusion experiments.
Medium
The cells were routinely cultured in complete medium consisting
of Dulbecco’s modified Eagle’s medium containing selected lots of
10% fetal calf serum and antibiotics (100 U/mL penicillin G, 100
Figure 1. Morphologic features of rat MSCs in culture. Phase con-
trast photomicrograph of twice-passaged culture of MSCs just
before implantation. Most adherent MSCs are practically fibro-
blastic in structure. Scale bar represents 30 µm.
Figure 2. Histochemical staining for β-gal activity of rat MSCs in
culture. The transfected MSCs showed clear staining for β-gal
activity. Transfection efficiency of the MSCs was approximately
100%. Scale bar represents 60 µm.
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µg/mL streptomycin, and 0.25 µg/mL amphotericin B; all obtained
from Gibco Laboratories, Grand Island, NY) at 37°C in a humidi-
fied atmosphere of 5% carbon dioxide.
MSC Labeling
GP+E86 murine ectropic retrovirus-packaging cells, which are
derived from National Institutes of Health 3T3 mouse fibroblasts,
were obtained from Dr Denis Cournoyer12 (McGill University,
Montreal, Quebec, Canada). The GP+E86 cells were transfected
with the purified plasmid DNA pMFG-LacZ in a 10:1 molar ratio
by means of the standard calcium phosphate transfection kit
(Pharmacia, Baie d’Urfe, Quebec, Canada). The LacZ gene
encodes for the production of bacterial β-galactosidase (β-gal).
These cells were plated at 25% confluence for 48 hours. The sec-
ond-passaged MSC growth medium was replaced with the super-
natant from the GP+E86 cells (containing the replication-defective
retrovirus carrying the β-gal reporter gene) to transfect the MSCs
overnight and then replaced with normal complete medium for the
next day. After 3 times of transfection, MSCs were then collected
(approximately 2 × 106 cells for one infusion) and resuspended in
50 µL of serum-free Dulbecco’s modified Eagle’s medium and
stored on ice until infusion into the ascending aorta. Some culture
plates were selected for histochemical staining in vitro for β-gal
activity. The cells were fixed in 2% formaldehyde and 0.2% glu-
taraldehyde in phosphate-buffered saline solution (PBS) at 4°C for
5 minutes. Staining for β-gal was accomplished at 37°C for 16
hours in a solution containing 1 mg/mL 5-bromo-4-chloro-3-
indoyl-β-D-galactoside (X-gal), 2% dimethylsulfoxide, 10 mmol/L
potassium ferricyanide, 10 mmol/L potassium ferrocyanide, 1
mmol/L magnesium chloride, and 0.02% hydrogel (Nonidet P-40)
in PBS, pH 7.3.
Infusion of MSCs 
Two weeks after the coronary ligation, the 12 recipient rats were
prepared for infusion of MSCs. Anesthesia was induced and main-
tained as above. The rats were intubated and connected to the ven-
tilator. The ascending aorta was exposed through an upper median
sternotomy and looped after dissection. Under direct vision, trans-
fected MSC suspension was then infused into the briefly distally
clamped ascending aorta (about 20 seconds). After the infusion,
the puncture bleeding site over the ascending aorta was controlled
by compression with gauze. The wound was then closed in layers.
Histology and Histochemical Staining for β-Gal
Activity
Two rats were put to death immediately after the infusion. The
hearts were excised and sliced along the short axis of the left ven-
tricle to 3-mm thick sections in series and fixed in 2% para-
formaldehyde in PBS for 2 hours. The sections were then cryo-
embedded in PBS overnight after protection with 20% sucrose.
The other 10 rats were taken for their final experiments 4 weeks
after the MSC infusion. After an overdose with pentobarbital, the
hearts were exposed and injected with 100 mL saline solution
(0.9%) through the apex of the left ventricle and then perfusion-
fixed with 2% paraformaldehyde in PBS. The hearts were excised,
sliced, and prepared as mentioned above. Cryosections 6 µm in
thickness were collected in each 3-mm section sample across a set
of gelatin-coated glass slides. One of every 10 cryosections was
collected for histochemical staining for β-gal activity as described
above. The sections were then counterstained with hematoxylin
and eosin. Tissue sections were examined with an Olympus micro-
scope (BX-FLA; Olympus America, Inc, Huntington Station, NY).
Digital images, transferred to a computer equipped with Image Pro
software (Media Cybernetics, Silver Spring, Md), were subse-
quently printed.
Histochemical Stain for Gap-Junction Protein,
Connexin 43
The gap junctions that constitute cardiac muscle–specific interca-
lated disks were demonstrated by histochemical stain for connexin
43, using rabbit anti-connexin antibodies (Zymed Laboratories Inc,
San Francisco, Calif). Diaminobenzidine was used as a chromogen
Figure 3. β-Gal–positive cells trapped within a coronary capillary
immediately after injection of MSCs. Staining for β-gal activity
followed by hematoxylin and eosin staining. Arrow, A capillary
endothelial cell. Scale bar represents 15 µm.
Figure 4. β-Gal–positive cells with cardiomyocyte morphologic
characteristics outside infarct scar 4 weeks after injection of
MSCs. Staining for β-gal activity followed by hematoxylin and
eosin staining. Arrows, Intercalated disklike structure.
Arrowhead, The nucleus of a β-gal–positive cell. Scale bar repre-
sents 15 µm.
702 The Journal of Thoracic and Cardiovascular Surgery • October 2001
ED
ITO
RIA
L
A
CD
G
TS
A
CD
ET
CSP
TX
to produce the brown color that represents gap junctions linking
cardiomyocytes together.13
Estimates of the Number of β-Gal–Positive Cells in the
Heart
We estimated the number of β-gal–positive cells present in the
heart immediately and 4 weeks after infusion by means of Weiss’s
method,14 which had been validated for the rodent heart model.
Estimates of cell counts reported represent the average pooled data
from 2 and 6 rats put to death immediately and 4 weeks after infu-
sion, respectively.
Results
Cultured MSCs were observed with a phase microscope to
assess the level of expansion and to verify the morphologic
features at each culture medium change. Most of the
hematopoietic stem cells were not adherent to the culture
plate and were removed with changes in medium. The
adherent cells were seen as individual cells or colonies of
only a few cells on day 6; however, they replicated rapidly
and formed colonies of up to 100 cells after the first week of
culture. By the end of second week, the colonies of adher-
ent cells had expanded in size, with each colony containing
several hundred to several thousand cells. Adherent MSCs
from rat legs had similar morphologic characteristics, most
being fibroblastic in appearance, with a few adipocytic,
polygonal cells (Figure 1). This phenotype was retained
throughout repeated passages under nonstimulating condi-
tions.
We transfected twice-passaged MSCs with replication-
defective retrovirus carrying the β-gal reporter gene as cell
labeling before their implantation. The transfected MSCs
showed clear histochemical staining for β-gal activity
(Figure 2). Transfection efficiency of the MSC culture was
almost 100%.
The rats were put to death at the following intervals after
the infusion of MSCs: immediately for 2 rats and at 4 weeks
for 10 rats. Gross examination of the excised hearts showed
clear myocardial scar formation (about 40% of left ventric-
ular free wall) on all 12 recipient rats. Cryosections of the
specimens were selected (as detailed in the “Methods” sec-
tion) for histochemical staining of β-gal activity to trace and
evaluate the morphologic and phenotype changes of infused
MSCs. Labeled cells could be identified in both rats that
were put to death immediately after infusion of MSCs and
in 6 of 10 rats put to death 4 weeks later.
Immediately after infusion of MSCs, β-gal–positive cells
were consistently found in all selected sections to be trapped
within the coronary capillaries surrounded by endothelial
cells all over the noninfarcted area (Figure 3).
Approximately 40,000 MSCs, that is, about 2% of the cells
infused into the ascending aorta, were estimated to have
been trapped within coronary capillaries immediately after
infusion. We failed to identify any β-gal–positive cells in the
infarction zone at this time. Four weeks after MSC infusion,
some β-gal positive cells could be found within the normal
myocardial area outside the infarct scar (Figure 4). They had
centrally located nuclei and were connected among them-
selves and with surrounding host cardiomyocytes (β-
gal–negative cells) by intercalated disklike structures, which
are characteristics of normal cardiomyocytes. However, the
β-gal–positive cells also could be detected individually or in
clusters within the myocardial scar (Figure 5). They
appeared unorganized and scattered in the infarction scar
with fibroblast-like morphologic features, similar to those
of the surrounding β-gal–negative (host) fibroblast cells.
Some β-gal–positive cells were found incorporated into
Surgery for Acquired Cardiovascular Disease Wang et al
Figure 5. β-Gal–positive cells with fibroblast-like morphologic
features in the myocardial scar 4 weeks after injection of MSCs.
Staining for β-gal activity followed by hematoxylin and eosin
staining. Arrows, β-Gal–positive cells. Scale bar represents 1.5
mm. Inset, Higher magnification of the area in the square. Scale
bar represents 30 µm.
Figure 6. β-Gal–positive cells incorporated into endocardium 4
weeks after injection of MSCs. Staining for β-gal activity followed
by hematoxylin and eosin staining. Arrow, Endocardium. Scale
bar represents 15 µm.
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endocardium (Figure 6) and coronary capillary endothelium
within or outside the infarcted scar area (Figure 7, A and B).
Using the calculation method described above, we estimat-
ed that approximately 500 β-gal–positive cells, including
about 400 fibroblast-like cells in the infarcted area, 50
myocytes within normal myocardial tissue, and 50 endothe-
lial cells all over the field, were present in one heart.
Tissue sections showing labeled cells with histologic fea-
tures of cardiomyocytes (as in Figure 4) were further stud-
ied immunohistochemically by means of antibodies against
connexin 43, a major constituent protein of gap junctions in
the intercalated disks of cardiac myofibers. The demonstra-
tion of such junctional structure (Figure 8) further confirms
the phenotype of the differentiated labeled cells and their
integration into the native cardiac myofibers.
Discussion
So that the fate of infused MSCs could be traced in this
study, they were retrovirally transfected with β-gal reporter
gene for cell labeling. Compared with other virus-based
gene transfer, retrovirus has less immunologic response and
longer gene expression.15 Such retroviral vectors are not
wild-type viruses but are modified replication-defective
viruses; thus, there is no risk of in vivo reinfection of neigh-
boring cells by those escaping from damaged labeled
cells.16 Furthermore, since the retroviral genes are integrat-
ed into the genome of the transfected cells, they can dupli-
cate themselves during cell division and label the progeny of
these cells as well. With the current transfection model, the
transfection efficiency in culture is approximately 100%
without obvious adverse effect on the cell growth. Our in
vivo control studies, including infusion of MSC culture
supernatant, nontransfected MSCs, or lysed transfected
MSCs while performing the same readout, confirmed the
specificity of this cell-labeling technique for our study (data
not shown).
Immediately after the infusion, the MSCs were trapped
within the coronary capillaries in the noninfarcted area. The
reason we could not find MSCs in the infarct scar at this
time may be related to the complete occlusion of involved
coronary artery (left coronary artery). Approximately
40,000 MSCs, about 2% of the cells infused into the ascend-
ing aorta, were detected immediately after infusion. This
number is lower than that of cells expected to partition to the
coronary circulation (around 5%). We suspect some cells
could have leaked out of the puncture hole on the ascending
aorta. Others might not have gone into the coronary circula-
tion because we infused cells into the ascending aorta above
the coronary orifices with forward blood flow. The problem
of the delivery system was beyond the scope of our study in
this small animal model. In larger animal models or future
human studies, selective coronary catheter infusion or sim-
ply increasing the number of infused cells will readily
enhance the quantity of cells delivered. However, 4 weeks
after infusion, the MSCs could be found both in the infarc-
tion scar and in the noninfarcted area outside the vascular
structure. The mechanism of the translocation of MSCs
from the vascular lumen into the myocardial interstitium is
unknown. MSCs had been shown to have the ability to
migrate in the in vivo experimental model.17 They may
migrate out of the vasculature and move from the nonin-
farcted area to the infarction scar. The other possible expla-
nation is that scar of myocardial infarction is not complete-
ly dead tissue. Studies have shown partial restitution and
Figure 7. β-Gal–positive cells incorporated into coronary capillaries 4 weeks after injection of MSCs. Staining for
β-gal activity followed by hematoxylin and eosin staining. A, Outside the infarct scar. Arrow, A capillary with β-
gal–positive cells in the area of subendocardial fibrosis. Arrowhead, Normal myocardium. Asterisk,
Endoventricular space. Scale bar represents 600 µm. Inset, Higher magnification. Arrow, The cross section of the
same capillary with β-gal–positive cells. Scale bar represents 15 µm. B, In the infarct scar. Arrow, The oblique
section of a capillary with β-gal–positive cells. Scale bar represents 15 µm.
A B
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function of the microvascular network within infarcted
myocardial tissue,18 which may serve as a route for MSCs
to engraft within the infarct scar. We noted that the number
of engrafted MSCs was considerably fewer in hearts 4
weeks after infusion. We speculate that perhaps some MSCs
did not migrate out of the coronary capillaries or that
engrafted MSCs might not have all survived. However, fur-
ther studies are required to elucidate such issues.
Nevertheless, MSCs in different myocardial microenvi-
ronments clearly have different fates. In the noninfarcted
area, they expressed the phenotypes of normal cardiomyo-
cytes and connected with surrounding host cardiomyocytes
by intercalated disklike structures. In the infarct scar, they
appeared primarily fibroblast-like. The mechanism of dif-
ferences in development and differentiation is not fully
understood. Recently, Makino and associates8 could identi-
fy a single clone of adherent fibroblast-like cells in the MSC
culture which, when treated with 5-azacytidine, would dif-
ferentiate into cells with some morphologic features of car-
diac muscle and expression of cardiac-specific genes in
vitro. MSCs have been proven to be involved in the mesen-
genic process for self-maintenance and repair of different
mesenchymal tissues.19,20 Moreover, the progeny of MSCs
expressed genes in a tissue-specific manner depending on
their destination.19 This homing ability and the capability to
acquire the phenotypes of different target tissues suggest
that the microenvironment plays a significant role for the
differentiation of these cells. Kopen, Prockop, and
Phinney17 injected MSCs into neonatal mouse brains and
found that these cells migrated throughout the forebrain 
and cerebellum. Moreover, MSCs mimic the behavior of
neural progenitor cells and differentiate into astrocytes and
even neurons, as indicated by the expression of neurofila-
ment. This suggests that MSCs can produce differentiated
progeny of a different embryonic dermal origin under the
influence of neonatal brain microenvironment. It is our
hypothesis that, in contrast to myocardial scar tissue, the
normal myocardial microenvironment may enable newly
arrived cells to be exposed, in an appropriate sequential
manner, to various cardiomyogenic specific growth factors
and differentiation molecules, such that the infused MSCs
could develop into fully mature cardiomyocytes. The fibro-
blast-like MSCs seen in the infarction scar could have dif-
ferentiated into primary fibroblasts, which are mature mes-
enchymal cells, or they could still maintain the multipotent
differentiation ability for future maturation. Clearly, further
studies are needed to assess the validity of these specula-
tions.
In this study, we also found some β-gal–positive donor
cells to differentiate into endothelium, which was incorpo-
rated into capillaries in the infarcted and noninfarcted areas.
It has been shown that some cells in MSC culture are posi-
tive for factor VIII–associated antigen,21 suggesting an
endothelial origin. Shi and associates22 suggested that a
subset of cells localized in the bone marrow could be mobi-
lized to the peripheral circulation and colonize endothelial
flow surfaces of vascular prostheses. Takahashi and cowork-
ers23 further demonstrated that ischemia and cytokines
could induce the mobilization of marrow-derived endothe-
lial progenitor cells for neovascularization. In this study, we
cannot prove that these capillaries incorporated with β-
gal–positive donor cells are newly formed. However, these
marrow-derived endothelial progenitor cells are likely to be
involved in the angiogenesis and vasculogenesis in the
remodeling process of myocardial infarction.
Both localized site-specific and global delivery of autol-
ogous MSCs may be of potential therapeutic benefit in
view of different cardiac pathologic conditions. For exam-
ple, intracoronary delivery of MSCs may be more suitable
for the treatment of heart failure resulting from diffuse car-
diomyopathy. Furthermore, although this animal model
does not allow us to conclude that MSCs normally partici-
pate in the healing and remodeling process after myocar-
dial infarction, our findings demonstrate that when expand-
ed MSCs are delivered to the coronary circulation of an
infarcted heart, they are capable of populating the heart and
differentiating along several lineages including cardiomy-
ocytes, fibroblasts, and endothelial cells. Thus, by extrapo-
lating the findings of Takahashi and associates23 in limb
ischemia, one may hypothesize that infarcted heart muscle
could also signal mobilization of MSCs to enter the circu-
lation and reach the coronary arteries, where they may par-
ticipate in myocyte replenishment, reactive fibrosis, and
Surgery for Acquired Cardiovascular Disease Wang et al
Figure 8. Immunohistochemical stain for connexin 43 in the inter-
calated disks (arrows), demonstrating the presence of gap junc-
tion unique to myocardium in the labeled (blue) myocytes.
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scar formation, as well as angiogenesis, in the postinfarc-
tion pathophysiologic remodeling process, involving both
the infarcted segment and the remote noninfarcted areas.
Thus, further studies to elucidate the role of MSCs in
myocardial infarction may lead to the possible clinical
applications of MSC implantation, enabling us to therapeu-
tically modulate the remodeling process after myocardial
infarction.
Conclusions
Our findings suggest that MSCs that have the potential to
traffic through the circulatory system to the injured heart are
capable of forming cardiomyocytes and other types of cells,
depending on the specific microenvironment. Endothelial
progenitor cells in the MSC population may be involved in
the postinfarction neovascularization process. Although we
believe our findings reported here contribute significantly to
the rapidly progressing field of stem cell therapy against
myocardial damage, further investigations designed to elu-
cidate the quantitative and functional aspects of this
approach will be required, because they were not within the
scope of the present study.
We appreciate the technical assistance of Minh Duong, BSc.
References
1. Chiu RCJ, Zibaitis A, Kao RL. Cellular cardiomyoplasty: myocardial
regeneration with satellite cell implantation. Ann Thorac Surg.
1995;60:12-8.
2. Soonpaa MH, Koh GY, Klug MG, Field LJ. Formation of nascent
intercalated disks between grafted fetal cardiomyocytes and host
myocardium. Science. 1994;264:98-101.
3. Li RK, Jia ZQ, Weisel RD, Mickle DAG, Zhang J, Mohabeer MK, et
al. Cardiomyocytes transplantation improves heart function. Ann
Thorac Surg. 1996;62:654-61.
4. Taylor DA, Atkins BZ, Hungspreugs P, Jones TR, Reedy MC,
Hutcheson KA, et al. Regenerating functional myocardium: improved
performance after skeletal myoblast transplantation. Nat Med.
1998;4:929-33.
5. Klug MG, Soonpaa MH, Koh GY, Field LJ. Genetically selected car-
diomyocytes from differentiating embryonic stem cells form stable
intracardiac grafts. J Clin Invest. 1996;98:216-24.
6. Clark BR, Jamieson C, Keating A. Human long-term bone marrow
culture. Methods Mol Biol. 1997;75:249-56.
7. Pittenger MF, Mackay AM, Beck SC, Jaiswal RK, Douglas R, Mosca
JD, et al. Multilineage potential of adult human mesenchymal stem
cells. Science. 1999;284:143-7.
8. Makino S, Fukuda K, Miyoshi S, Konishi F, Kodama H, Pan J, et al.
Cardiomyocytes can be generated from marrow stromal cells in vitro.
J Clin Invest. 1999;103:697-705.
9. Wang JS, Shum-Tim D, Galipeau J, Chedrawy E, Eliopoulos N, Chiu
RCJ. Marrow stromal cells for cellular cardiomyoplasty: feasibility
and clinical advantages. J Thorac Cardiovasc Surg. 2000;120:999-
1006.
10. Connold AL, Frischknecht R, Dimitrakos M, Vrbova G. The survival
of embryonic cardiomyocytes transplanted into damaged host rat
myocardium. J Muscle Res Cell Motil. 1997;18:63-70.
11. Wakitani S, Saito T, Caplan AI. Myogenic cells derived from rat bone
marrow mesenchymal stem cells exposed to 5-azacytidine. Muscle
Nerve. 1995;18:1417-26.
12. Momparler RL, Laliberte J, Eliopoulos N, Beausejour C, Cournoyer
D. Transfection of murine fibroblast cells with human cytidine deam-
inase cDNA confers resistance to cytosine arabinoside. Anticancer
Drugs. 1996;7:266-74.
13. Nagy JI, Li WE, Roy C, Doble BW, Gilchrist JS, Kardami E, et al.
Selective monoclonal antibody recognition and cellular localization of
an unphosphorylated form of connexin 43. Exp Cell Res.
1997;236:127-36.
14. Weiss L. Biomechanical destruction of cancer cells in the heart: a rate
regulator of hematogenous metastasis. Invasion Metastasis.
1988;8:228-37.
15. Onifer SM, White LA, Whittemore SR, Holets VR. In vitro labeling
strategies for identifying primary neural tissue and a neuronal cell line
after transplantation in the CNS. Cell Transplant. 1993;2:131-49.
16. Jaalouk DE, Eliopoulos N, Couture C, Mader S, Galipeau J.
Glucocorticoid-inducible retrovector for regulated transgene expres-
sion in genetically engineered bone marrow stromal cells. Hum Gene
Ther. 2000;11:1837-49.
17. Kopen GC, Prockop DJ, Phinney DG. Marrow stromal cells migrate
throughout forebrain and cerebellum, and they differentiate into astro-
cytes after injection into neonatal mouse brains. Proc Natl Acad Sci U
S A. 1999;96:10711-6.
18. Huwer H, Rissland J, Vollmar B, Nikoloudakis N, Welter C, Menger
MD, et al. Angiogenesis and microvascularization after cryothermia-
induced myocardial infarction: a quantitative fluorescence microscop-
ic study in rats. Basic Res Cardiol. 1999;94:85-93.
19. Pereira RF, Halford KW, O’Hara MD, Leeper DB, Sokolov BP,
Pollard MD, et al. Cultured adherent cells from marrow can serve as
long-lasting precursor cells for bone, cartilage, and lung in irradiated
mice. Proc Natl Acad Sci U S A. 1995;92:4857-61.
20. Caplan AI. The mesengenic process. Clin Plast Surg. 1994;21:429-35.
21. Singer JW, Charbond P, Keating A, Nemunaitis J, Raugi G, Wight TN,
et al. Simian virus-40 transformed adherent cells from human long-
term marrow cultures: clone cells produced with “stromal” and
hematopoietic characteristics. Blood. 1987;70:464-74.
22. Shi BQ, Rafii S, Wu MHD, Wijelath ES, Yu C, Ishida A, et al.
Evidence for circulating bone marrow-derived endothelial cells.
Blood. 1998;92:362-7.
23. Takahashi T, Kalka C, Masuda H, Chen D, Silver M, Kearney M, et al.
Ischemia- and cytokine-induced mobilization of bone marrow-derived
endothelial progenitor cells for neovascularization. Nat Med.
1999;5:434-4.
